Skip to content
DataLookout
Menu

NCT07790380

FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Start date changed from estimate of Oct 10, 2026 to Oct 13, 2026
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Overall Survival
Timeframe: Until death, assessed up to approximately 2 years

Secondary (5)

Progression-free survival (PFS) by investigator assessment
Objective response rate (ORR) by investigator assessment
Duration of response (DOR) by investigator assessment
Disease control rate (DCR) by investigator assessment
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs)

Arms and interventions

Treatment group A: FH-006Experimental
Treatment group B: Paclitaxel, Docetaxel, Irinotecan.Active comparator

Drugs: FH-006, Paclitaxel, Docetaxel, Irinotecan

Sites

1 site in 1 country

  • Shandong Provincial Cancer HospitalJinan, Shandong, China